These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 27067220)
1. [Development of mesangial immunoglobulin IgA glomerulonephritis and p-ANCA positivity in a patient with psoriatic arthritis]. Nazzaro P; Battaglia R; D'Altri C; Marangi AL; Perniola M; Rodio A; De Padova F G Ital Nefrol; 2016; 33(2):. PubMed ID: 27067220 [TBL] [Abstract][Full Text] [Related]
2. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Haas M; Jafri J; Bartosh SM; Karp SL; Adler SG; Meehan SM Am J Kidney Dis; 2000 Oct; 36(4):709-18. PubMed ID: 11007672 [TBL] [Abstract][Full Text] [Related]
3. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Michel M; Henri P; Vincent FB; Leon N; Marcelli C Joint Bone Spine; 2013 Dec; 80(6):660-3. PubMed ID: 23816503 [TBL] [Abstract][Full Text] [Related]
11. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066 [TBL] [Abstract][Full Text] [Related]
12. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Massarotti M; Marasini B Int J Immunopathol Pharmacol; 2009; 22(2):547-9. PubMed ID: 19505409 [TBL] [Abstract][Full Text] [Related]
13. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. Perrotta FM; Marchesoni A; Lubrano E J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925 [TBL] [Abstract][Full Text] [Related]
14. [Autoimmune aspects of treatment with TNF-alpha inhibitors]. Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135 [TBL] [Abstract][Full Text] [Related]
16. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
18. [Significance of IGA antigliadin antibodies during primary glomerulonephritis with mesangial IGA deposits]. Rostoker G; Delprato S; Benmaadi A; Petit-Phar M; Andre C; Laurent J; Lang P; Weil B; Lagrue G Ann Med Interne (Paris); 1989; 140(7):571-4. PubMed ID: 2610450 [TBL] [Abstract][Full Text] [Related]
19. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers. Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G; J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493 [TBL] [Abstract][Full Text] [Related]
20. Double Infection in a Patient with Psoriatic Arthritis Under TNF-alpha Blockers Therapy: A Case Report. Caroleo B; Migliore A; Cione E; Zampogna S; Perticone F; Sarro G; Gallelli L Curr Drug Saf; 2019; 14(2):147-150. PubMed ID: 30648521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]